EP0851759A4 - Verbindungen und verfahren dazu - Google Patents

Verbindungen und verfahren dazu

Info

Publication number
EP0851759A4
EP0851759A4 EP96930743A EP96930743A EP0851759A4 EP 0851759 A4 EP0851759 A4 EP 0851759A4 EP 96930743 A EP96930743 A EP 96930743A EP 96930743 A EP96930743 A EP 96930743A EP 0851759 A4 EP0851759 A4 EP 0851759A4
Authority
EP
European Patent Office
Prior art keywords
compounds
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96930743A
Other languages
English (en)
French (fr)
Other versions
EP0851759A1 (de
Inventor
Robert A Daines
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP0851759A1 publication Critical patent/EP0851759A1/de
Publication of EP0851759A4 publication Critical patent/EP0851759A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/22—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP96930743A 1995-09-05 1996-09-05 Verbindungen und verfahren dazu Withdrawn EP0851759A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US355695P 1995-09-05 1995-09-05
US3556P 1995-09-05
PCT/US1996/014347 WO1997009046A1 (en) 1995-09-05 1996-09-05 Compounds and methods

Publications (2)

Publication Number Publication Date
EP0851759A1 EP0851759A1 (de) 1998-07-08
EP0851759A4 true EP0851759A4 (de) 2000-12-06

Family

ID=21706424

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96930743A Withdrawn EP0851759A4 (de) 1995-09-05 1996-09-05 Verbindungen und verfahren dazu

Country Status (3)

Country Link
EP (1) EP0851759A4 (de)
JP (1) JPH11512396A (de)
WO (1) WO1997009046A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6753150B2 (en) * 1998-10-05 2004-06-22 The Trustees Of Columbia University In The City Of New York Method for determining whether a compound is capable of inhibiting the interaction of a peptide with rage
PL374017A1 (en) 2002-06-05 2005-09-19 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
US7842808B2 (en) 2002-06-05 2010-11-30 Bristol-Myers Squibb Company Anti-migraine spirocycles
WO2005000807A2 (en) * 2003-06-26 2005-01-06 Merck & Co., Inc. Benzodiazepine cgrp receptor antagonists
AR046787A1 (es) 2003-12-05 2005-12-21 Bristol Myers Squibb Co Agentes antimigrana heterociclicos
RS20060382A (en) 2003-12-05 2008-09-29 Bristol-Myers Squibb Company, Calcitonin gene related peptide receptor antagonists
TW200533398A (en) 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
CN101014345A (zh) * 2004-09-09 2007-08-08 默克公司 三环酰苯胺螺环内酰胺cgrp受体拮抗剂
JP2008512489A (ja) * 2004-09-13 2008-04-24 メルク エンド カムパニー インコーポレーテッド 三環式アニリドスピロヒダントインｃｇｒｐ受容体拮抗薬
US7384930B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7384931B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7449586B2 (en) 2004-12-03 2008-11-11 Bristol-Myers Squibb Company Processes for the preparation of CGRP-receptor antagonists and intermediates thereof
US7834007B2 (en) 2005-08-25 2010-11-16 Bristol-Myers Squibb Company CGRP antagonists
PT2380592T (pt) 2005-11-14 2018-06-06 Teva Pharmaceuticals Int Gmbh Anticorpos antagonistas dirigidos contra o péptido relacionado com o gene da calcitonina e métodos utilizando os mesmos
MX2010009722A (es) 2008-03-04 2010-09-30 Pfizer Ltd Procedimiento de tratamiento del dolor cronico.
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
BR112012004464B8 (pt) 2009-08-28 2021-05-25 Labrys Biologics Inc uso de um anticorpo antagonista anti-cgrp para preparar uma composição farmacêutica para tratar e/ou prevenir dor visceral e/ou um ou mais sintomas de dor visceral, em que a dor visceral está associada á cistite intersticial (ic), e dita composição farmacêutica
WO2012021291A2 (en) * 2010-08-09 2012-02-16 University Of Maryland, Baltimore Methods of treating obstructive lung diseases using bitter tastants
ES2873837T3 (es) 2011-05-20 2021-11-04 H Lundbeck As Composiciones anti CGRP y uso de las mismas
CN108359008B (zh) 2011-05-20 2022-03-29 H.伦德贝克公司 抗cgrp或抗cgrp-r抗体或抗体片段用于治疗或预防慢性和急性形式的腹泻的用途
CN107827982B (zh) 2011-05-20 2021-07-06 H.伦德贝克公司 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途
RS65360B1 (sr) 2014-03-21 2024-04-30 Teva Pharmaceuticals Int Gmbh Antagonistička antitela specifična za peptid genski srodan kalcitoninu i postupci njihove upotrebe
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
WO2018031216A1 (en) * 2016-08-12 2018-02-15 Steven Rothman Treatment of disorders of sexual arousal with local application of agents that increase membrane excitability
WO2018055574A1 (en) 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating refractory migraine
SG11202106766SA (en) 2019-01-08 2021-07-29 H Lundbeck As Acute treatment and rapid treatment of headache using anti-cgrp antibodies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA873893A (en) * 1971-06-22 P. Yardley John Cinchona alkaloid derivatives
US3929795A (en) * 1968-07-02 1975-12-30 Hoffmann La Roche Processes and intermediates for quinine, quinidine, isomers and derivatives thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DAINES R A ET AL: "Quinine analogs as non-peptide calcitonin gene-related peptide (CGRP) receptor antagonists", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,GB,OXFORD, vol. 7, no. 20, 21 October 1997 (1997-10-21), pages 2673 - 2676, XP004136510, ISSN: 0960-894X *
See also references of WO9709046A1 *

Also Published As

Publication number Publication date
WO1997009046A1 (en) 1997-03-13
EP0851759A1 (de) 1998-07-08
JPH11512396A (ja) 1999-10-26

Similar Documents

Publication Publication Date Title
GB2298422B (en) Compounds and their use
IL117177A0 (en) Benzopyran-containing compounds and method for their use
EP0851759A4 (de) Verbindungen und verfahren dazu
EP0836617A4 (de) Parevine und tachyteprine
HU9601680D0 (en) Benzisothiazolyl-substituted aminomethyl-chromanes
DE59602888D1 (en) Breitstreckaggregat
DE59602283D1 (en) Inchbremseinrichtung
DE59602030D1 (en) Zellige polyurethan-elastomere
EP0799225A4 (de) Verbindungen und verfahren
DE59505396D1 (en) Handhobelmaschine
GB9616563D0 (en) Compounds and methods
GB9525234D0 (en) Process compound and use
AP9600802A0 (en) Libricant
GB9504876D0 (en) Compounds and process
DE59600830D1 (en) Breitstrahldüse
GB9722556D0 (en) Methods
EP0934345A4 (de) Verbindungen und verfahren
GB9516970D0 (en) Methods
GB9516940D0 (en) Methods
GB9510639D0 (en) Methods
GB9505905D0 (en) Methods
GB9523379D0 (en) Compound and method
AU126796S (en) Book-ends
AU126739S (en) Gamesboard
AU125853S (en) Tea - towel

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980320

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE ES FR GB IT LI NL

A4 Supplementary search report drawn up and despatched

Effective date: 20001024

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): BE CH DE ES FR GB IT LI NL

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20010109